HealthEquity Reports Second Quarter Ended July 31, 2023 Financial Results

Delivers Record HSA Asset Growth, Margin Expansion

Highlights of the second quarter include:

• Revenue of $243.5 million, an increase of 18% compared to $206.1 million in Q2 FY23.
• Net income of $10.6 million, compared to net loss of $10.7 million in Q2 FY23, with non-GAAP net income of $45.6 million, an increase of 62% compared to $28.1 million in Q2 FY23.
• Net income per diluted share of $0.12, compared to net loss per diluted share of $0.13 in Q2 FY23, with non-GAAP net income per diluted share of $0.53, compared to $0.33 in Q2 FY23.
• Adjusted EBITDA of $88.1 million, an increase of 31% compared to $67.0 million in Q2 FY23.
• 8.2 million HSAs, an increase of 9% compared to Q2 FY23.
• Total HSA Assets of $23.2 billion, an increase of 13% compared to Q2 FY23.
• 15.0 million Total Accounts, including both HSAs and complementary CDBs, an increase of 3% compared to Q2 FY23.
  

DRAPER, Utah, Sept. 05, 2023 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) ("HealthEquity" or the "Company"), the nation's largest health savings account ("HSA") custodian, today announced financial results for its second quarter ended July 31, 2023.

"HealthEquity’s 8.2 million HSA Members grew their health savings by $883 million, including strong contributions from the 156,000 new HSA Members Team Purple welcomed during the quarter," said Jon Kessler, President and CEO of HealthEquity. "Strong member and balance growth, improving custodial yields, and an ongoing service technology rollout all contributed to 360bps of year-over-year expansion of adjusted EBITDA as a percentage of revenue and record operating cash flow."

Second quarter financial results

Revenue for the second quarter ended July 31, 2023 was $243.5 million, an increase of 18% compared to $206.1 million for the second quarter ended July 31, 2022. Revenue this quarter included: service revenue of $105.7 million, custodial revenue of $98.9 million, and interchange revenue of $38.9 million.

HealthEquity reported net income of $10.6 million, or $0.12 per diluted share, and non-GAAP net income of $45.6 million, or $0.53 per diluted share, for the second quarter ended July 31, 2023. The Company reported a net loss of $10.7 million, or $0.13 per diluted share, and non-GAAP net income of $28.1 million, or $0.33 per diluted share, for the second quarter ended July 31, 2022.

Adjusted EBITDA was $88.1 million for the second quarter ended July 31, 2023, an increase of 31% compared to the second quarter ended July 31, 2022. Adjusted EBITDA was 36% of revenue, compared to 33% for the second quarter ended July 31, 2022.

Account and asset metrics

HSAs as of July 31, 2023 were 8.2 million, an increase of 9% year over year, including 574,000 HSAs with investments, an increase of 11% year over year. Total Accounts as of July 31, 2023 were 15.0 million, including 6.8 million other consumer-directed benefits ("CDBs").

Total HSA Assets as of July 31, 2023 were $23.2 billion, an increase of 13% year over year. Total HSA Assets included $14.0 billion of HSA cash and $9.2 billion of HSA investments. Client-held funds, which are deposits held on behalf of our Clients to facilitate administration of our CDBs, and from which we generate custodial revenue, were $0.8 billion as of July 31, 2023.

Business outlook

For the fiscal year ending January 31, 2024, management expects revenue of $980 million to $990 million. Its outlook for net income is between $19 million and $24 million, resulting in net income of $0.21 to $0.27 per diluted share. Its outlook for non-GAAP net income, calculated using the method described below, is between $171 million and $179 million, resulting in non-GAAP net income per diluted share of $1.97 to $2.06 (based on an estimated 87 million diluted weighted-average shares outstanding). Management expects Adjusted EBITDA of $338 million to $348 million.

See "Non-GAAP financial information" below for definitions of our Adjusted EBITDA and non-GAAP net income. A reconciliation of the non-GAAP financial measures used throughout this release to the most comparable GAAP financial measures is included with the financial tables at the end of this release.

Conference call

HealthEquity management will host a conference call at 4:30 pm (Eastern Time) on Tuesday, September 5, 2023 to discuss the fiscal 2024 second quarter financial results. The conference call will be accessible by dialing 1-833-630-1956, or 1-412-317-1837 for international callers, and referencing conference ID "HealthEquity, Inc. call." A live audio webcast of the call will be available on the investor relations section of our website at http://ir.healthequity.com.

Non-GAAP financial information

To supplement our financial information presented on a GAAP basis, we disclose non-GAAP financial measures, including Adjusted EBITDA, non-GAAP net income, and non-GAAP net income per diluted share.

• Adjusted EBITDA is adjusted earnings before interest, taxes, depreciation and amortization, amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, amortization of incremental costs to obtain a contract, costs associated with unused office space, and certain other non-operating items.
• Non-GAAP net income is calculated by adding back to GAAP net income (loss) before income taxes the following items: amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, costs associated with unused office space, and losses on extinguishment of debt, and subtracting a non-GAAP tax provision using a normalized non-GAAP tax rate.
• Non-GAAP net income per diluted share is calculated by dividing non-GAAP net income by diluted weighted-average shares outstanding.
  

Non-GAAP financial measures should be considered in addition to results prepared in accordance with GAAP and should not be considered as a substitute for, or superior to, GAAP results. We believe that these non-GAAP financial measures provide useful information to management and investors regarding certain financial and business trends relating to the Company's financial condition and results of operations. The Company cautions investors that non-GAAP financial information, by its nature, departs from GAAP; accordingly, its use can make it difficult to compare current results with results from other reporting periods and with the results of other companies. In addition, while amortization of acquired intangible assets is being excluded from non-GAAP net income, the revenue generated from those acquired intangible assets is not excluded. Whenever we use these non-GAAP financial measures, we provide a reconciliation of the applicable non-GAAP financial measure to the most closely applicable GAAP financial measure. Investors are encouraged to review the related GAAP financial measures and the reconciliation of the non-GAAP financial measures to their most directly comparable GAAP financial measure as detailed in the tables below.

About HealthEquity

HealthEquity and its subsidiaries administer HSAs and other consumer-directed benefits for our 15 million accounts in partnership with employers, benefits advisors, and health and retirement plan providers who share our mission to connect health and wealth and value our culture of remarkable "Purple" service. For more information, visit www.healthequity.com.

Forward-looking statements

This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding our industry, business strategy, plans, goals and expectations concerning our markets and market position, product expansion, future operations, expenses and other results of operations, revenue, margins, profitability, acquisition synergies, future efficiencies, tax rates, capital expenditures, liquidity and capital resources and other financial and operating information. When used in this discussion, the words "may," "believes," "intends," "seeks," "aims," "anticipates," "plans," "estimates," "expects," "should," "assumes," "continues," "could," "will," "future" and the negative of these or similar terms and phrases are intended to identify forward-looking statements in this press release.

Forward-looking statements reflect our current expectations regarding future events, results or outcomes. These expectations may or may not be realized. Although we believe the expectations reflected in the forward-looking statements are reasonable, we can give you no assurance these expectations will prove to be correct. Some of these expectations may be based upon assumptions, data or judgments that prove to be incorrect. Actual events, results and outcomes may differ materially from our expectations due to a variety of known and unknown risks, uncertainties and other factors. Although it is not possible to identify all of these risks and factors, they include, among others, risks related to the following:

• our dependence on the continued availability and benefits of tax-advantaged HSAs and other CDBs;
• our ability to adequately place and safeguard our custodial assets, or the failure of any of our depository or insurance company partners;
• the impact from a decline in interest rate levels on our financial results;
• our ability to realize the anticipated financial and other benefits from combining the operations of recent and future acquisitions with our business successfully;
• our ability to compete effectively in a rapidly evolving healthcare and benefits administration industry;
• our ability to successfully identify, acquire and integrate additional portfolio purchases or acquisition targets;
• the significant competition we face and may face in the future, including from those with greater resources than us;
• the impact of societal and economic changes arising out of the COVID-19 pandemic on the Company, our operations and our financial results;
• our reliance on the availability and performance of our technology and communications systems;
• potential future cybersecurity breaches of our technology and communications systems and other data interruptions, including resulting costs and liabilities, reputational damage and loss of business;
• the current uncertain healthcare environment, including changes in healthcare programs and expenditures and related regulations;
• our ability to comply with current and future privacy, healthcare, tax, ERISA, investment adviser and other laws applicable to our business;
• our reliance on partners and third-party vendors for distribution and important services;
• our ability to develop and implement updated features for our technology and communications systems; and
• our reliance on our management team and key team members.
  

For a detailed discussion of these and other risk factors, please refer to the risks detailed in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the fiscal year ended January 31, 2023 and subsequent periodic and current reports. Past performance is not necessarily indicative of future results. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Investor Relations Contact
Richard Putnam
801-231-0697
rputnam@healthequity.com

HealthEquity, Inc. and subsidiaries
Condensed consolidated balance sheets

(in thousands, except par value)	July 31, 2023			January 31, 2023
	(unaudited)
Assets
Current assets
Cash and cash equivalents	$	290,345		$	254,266
Accounts receivable, net of allowance for doubtful accounts of $4,639 and $4,989 as of July 31, 2023 and January 31, 2023, respectively		92,581			96,835
Other current assets		39,631			31,792
Total current assets		422,557			382,893
Property and equipment, net		9,145			12,862
Operating lease right-of-use assets		51,976			56,461
Intangible assets, net		881,937			936,359
Goodwill		1,648,145			1,648,145
Other assets		52,696			52,180
Total assets	$	3,066,456		$	3,088,900
Liabilities and stockholders’ equity
Current liabilities
Accounts payable	$	12,543		$	13,899
Accrued compensation		31,421			45,835
Accrued liabilities		49,281			43,668
Current portion of long-term debt		—			17,500
Operating lease liabilities		10,026			10,159
Total current liabilities		103,271			131,061
Long-term liabilities
Long-term debt, net of issuance costs		873,581			907,838
Operating lease liabilities, non-current		52,371			58,988
Other long-term liabilities		13,092			12,708
Deferred tax liability		74,527			82,665
Total long-term liabilities		1,013,571			1,062,199
Total liabilities		1,116,842			1,193,260
Commitments and contingencies
Stockholders’ equity
Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares issued and outstanding as of July 31, 2023 and January 31, 2023, respectively		—			—
Common stock, $0.0001 par value, 900,000 shares authorized, 85,612 and 84,758 shares issued and outstanding as of July 31, 2023 and January 31, 2023, respectively		9			8
Additional paid-in capital		1,785,014			1,745,716
Accumulated earnings		164,591			149,916
Total stockholders’ equity		1,949,614			1,895,640
Total liabilities and stockholders’ equity	$	3,066,456		$	3,088,900

HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of operations and comprehensive income (loss) (unaudited)

	Three months ended July 31,								Six months ended July 31,
(in thousands, except per share data)		2023				2022				2023				2022
Revenue
Service revenue	$	105,719			$	103,034			$	210,831			$	207,382
Custodial revenue		98,917				65,599				193,358				124,964
Interchange revenue		38,913				37,509				83,792				79,475
Total revenue		243,549				206,142				487,981				411,821
Cost of revenue
Service costs		76,543				74,914				157,098				155,788
Custodial costs		9,133				7,090				18,133				13,731
Interchange costs		6,943				6,326				13,994				13,317
Total cost of revenue		92,619				88,330				189,225				182,836
Gross profit		150,930				117,812				298,756				228,985
Operating expenses
Sales and marketing		19,123				15,843				39,058				32,403
Technology and development		54,767				46,580				107,959				91,763
General and administrative		27,090				25,937				51,984				49,664
Amortization of acquired intangible assets		23,166				24,181				46,332				47,879
Merger integration		2,044				7,683				5,502				16,977
Total operating expenses		126,190				120,224				250,835				238,686
Income (loss) from operations		24,740				(2,412	)			47,921				(9,701	)
Other expense
Interest expense		(13,272	)			(11,493	)			(28,269	)			(21,954	)
Other income (expense), net		2,756				32				4,584				(269	)
Total other expense		(10,516	)			(11,461	)			(23,685	)			(22,223	)
Income (loss) before income taxes		14,224				(13,873	)			24,236				(31,924	)
Income tax provision (benefit)		3,643				(3,219	)			9,561				(7,631	)
Net income (loss) and comprehensive income (loss)	$	10,581			$	(10,654	)		$	14,675			$	(24,293	)
Net income (loss) per share:
Basic	$	0.12			$	(0.13	)		$	0.17			$	(0.29	)
Diluted	$	0.12			$	(0.13	)		$	0.17			$	(0.29	)
Weighted-average number of shares used in computing net income (loss) per share:
Basic		85,533				84,443				85,286				84,236
Diluted		86,341				84,443				86,356				84,236

HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of cash flows (unaudited)

	Six months ended July 31,
(in thousands)		2023				2022
Cash flows from operating activities:
Net income (loss)	$	14,675			$	(24,293	)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization		77,387				80,226
Stock-based compensation		38,277				32,140
Amortization of debt discount and issuance costs		1,461				1,639
Loss on extinguishment of debt		1,157				—
Other non-cash items		—				269
Deferred taxes		(8,138	)			(7,558	)
Changes in operating assets and liabilities:
Accounts receivable, net		4,254				(3,161	)
Other assets		(8,526	)			(1,546	)
Operating lease right-of-use assets		6,594				4,117
Accrued compensation		(14,675	)			(4,973	)
Accounts payable, accrued liabilities, and other current liabilities		3,970				(25,586	)
Operating lease liabilities, non-current		(8,175	)			(3,594	)
Other long-term liabilities		384				(454	)
Net cash provided by operating activities		108,645				47,226
Cash flows from investing activities:
Purchases of software and capitalized software development costs		(18,794	)			(24,215	)
Purchases of property and equipment		(590	)			(2,384	)
Acquisitions of HSA portfolios		—				(68,725	)
Net cash used in investing activities		(19,384	)			(95,324	)
Cash flows from financing activities:
Principal payments on long-term debt		(54,375	)			(4,375	)
Settlement of client-held funds obligation, net		(161	)			(991	)
Proceeds from exercise of common stock options		1,354				4,936
Net cash used in financing activities		(53,182	)			(430	)
Increase (decrease) in cash and cash equivalents		36,079				(48,528	)
Beginning cash and cash equivalents		254,266				225,414
Ending cash and cash equivalents	$	290,345			$	176,886

HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of cash flows (unaudited) (continued)

	Six months ended July 31,
(in thousands)		2023			2022
Supplemental cash flow data:
Interest expense paid in cash	$	23,504		$	19,450
Income tax payments, net		15,113			573
Supplemental disclosures of non-cash investing and financing activities:
Purchases of software and capitalized software development costs included in accounts payable, accrued liabilities, or accrued compensation		3,228			5,040
Purchases of property and equipment included in accounts payable or accrued liabilities		300			356
Acquisitions of HSA portfolios included in accounts payable or accrued liabilities		—			1,849
Exercise of common stock options receivable		50			8
Increase in goodwill due to measurement period adjustments, net		—			163

Stock-based compensation expense (unaudited)

Total stock-based compensation expense included in the condensed consolidated statements of operations and comprehensive income (loss) is as follows:

	Three months ended July 31,						Six months ended July 31,
(in thousands)		2023			2022			2023			2022
Cost of revenue	$	4,714		$	3,998		$	8,549		$	7,005
Sales and marketing		3,478			2,553			6,257			4,567
Technology and development		4,283			2,963			9,175			6,343
General and administrative		7,598			8,640			14,296			14,225
Total stock-based compensation expense	$	20,073		$	18,154		$	38,277		$	32,140

Total Accounts (unaudited)

(in thousands, except percentages)		July 31, 2023			July 31, 2022			% Change			January 31, 2023
HSAs		8,164			7,523			9	%		7,984
New HSAs from sales - Quarter-to-date		156			196			(20)	%		445
New HSAs from sales - Year-to-date		290			355			(18)	%		971
New HSAs from acquisitions - Year-to-date		—			90			(100)	%		90
HSAs with investments		574			516			11	%		541
CDBs		6,831			7,023			(3)	%		6,933
Total Accounts		14,995			14,546			3	%		14,917
Average Total Accounts - Quarter-to-date		14,954			14,497			3	%		14,677
Average Total Accounts - Year-to-date		14,967			14,462			3	%		14,531

HSA Assets (unaudited)

(in millions, except percentages)	July 31, 2023			July 31, 2022			% Change			January 31, 2023
HSA cash	$	14,021		$	13,097		7	%		$	14,199
HSA investments		9,181			7,441		23	%			7,947
Total HSA Assets		23,202			20,538		13	%			22,146
Average daily HSA cash - Year-to-date		14,048			12,924		9	%			13,049
Average daily HSA cash - Quarter-to-date		14,001			12,941		8	%			13,375

Client-held funds (unaudited)

(in millions, except percentages)	July 31, 2023			July 31, 2022			% Change			January 31, 2023
Client-held funds	$	811		$	801		1	%		$	901
Average daily Client-held funds - Year-to-date		896			852		5	%			827
Average daily Client-held funds - Quarter-to-date		891			839		6	%			809

Reconciliation of net income (loss) to Adjusted EBITDA (unaudited)

	Three months ended July 31,								Six months ended July 31,
(in thousands)		2023				2022				2023				2022
Net income (loss)	$	10,581			$	(10,654	)		$	14,675			$	(24,293	)
Interest income		(2,484	)			(89	)			(4,082	)			(141	)
Interest expense		13,272				11,493				28,269				21,954
Income tax provision (benefit)		3,643				(3,219	)			9,561				(7,631	)
Depreciation and amortization		15,180				16,559				31,055				32,347
Amortization of acquired intangible assets		23,166				24,181				46,332				47,879
Stock-based compensation expense		20,073				18,154				38,277				32,140
Merger integration expenses		2,044				7,683				5,502				16,977
Acquisition costs		—				47				—				53
Amortization of incremental costs to obtain a contract		1,350				1,074				2,654				2,142
Costs associated with unused office space		1,286				1,313				2,302				2,607
Other		—				501				153				1,345
Adjusted EBITDA	$	88,111			$	67,043			$	174,698			$	125,379

Reconciliation of net income outlook to Adjusted EBITDA outlook (unaudited)

	Outlook for the year ending
(in millions)	January 31, 2024
Net income	$19 - 24
Interest income	(11)
Interest expense	55
Income tax provision	18 - 23
Depreciation and amortization	60
Amortization of acquired intangible assets	93
Stock-based compensation expense	79
Merger integration expenses	15
Amortization of incremental costs to obtain a contract	5
Costs associated with unused office space	4
Other expense	1
Adjusted EBITDA	$338 - 348

Reconciliation of net income (loss) to non-GAAP net income (unaudited)

	Three months ended July 31,							Six months ended July 31,
(in thousands, except per share data)		2023			2022				2023			2022
Net income (loss)	$	10,581		$	(10,654	)		$	14,675		$	(24,293	)
Income tax provision (benefit)		3,643			(3,219	)			9,561			(7,631	)
Income (loss) before income taxes - GAAP		14,224			(13,873	)			24,236			(31,924	)
Non-GAAP adjustments:
Amortization of acquired intangible assets		23,166			24,181				46,332			47,879
Stock-based compensation expense		20,073			18,154				38,277			32,140
Merger integration expenses		2,044			7,683				5,502			16,977
Acquisition costs		—			47				—			53
Costs associated with unused office space		1,286			1,313				2,302			2,607
Loss on extinguishment of debt		—			—				1,157			—
Total adjustments to income (loss) before income taxes - GAAP		46,569			51,378				93,570			99,656
Income before income taxes - Non-GAAP		60,793			37,505				117,806			67,732
Income tax provision - Non-GAAP (1)		15,199			9,376				29,452			16,933
Non-GAAP net income		45,594			28,129				88,354			50,799
Diluted weighted-average shares		86,341			84,443				86,356			84,236
Non-GAAP net income per diluted share	$	0.53		$	0.33			$	1.02		$	0.60

(1) The Company utilizes a normalized non-GAAP tax rate to provide better consistency across the interim reporting periods within a given fiscal year by eliminating the effects of non-recurring and period-specific items, which can vary in size and frequency, and which are not necessarily reflective of the Company’s longer-term operations. The normalized non-GAAP tax rate applied to each period presented was 25%. The Company may adjust its non-GAAP tax rate as additional information becomes available and in conjunction with any other significant events occurring that may materially affect this rate, such as merger and acquisition activity, changes in business outlook, or other changes in expectations regarding tax regulations.

Reconciliation of net income outlook to non-GAAP net income outlook (unaudited)

	Outlook for the year ending
(in millions, except per share data)	January 31, 2024
Net income	$19 - 24
Income tax provision	18 - 23
Income before income taxes - GAAP	37 - 47
Non-GAAP adjustments:
Amortization of acquired intangible assets	93
Stock-based compensation expense	79
Merger integration expenses	15
Costs associated with unused office space	4
Total adjustments to income before income taxes - GAAP	191
Income before income taxes - Non-GAAP	228 - 238
Income tax provision - Non-GAAP (1)	57 - 59
Non-GAAP net income	$171 - 179
Diluted weighted-average shares	87
Non-GAAP net income per diluted share (2)	$1.97 - 2.06

(1) The Company utilizes a normalized non-GAAP tax rate to provide better consistency across the interim reporting periods within a given fiscal year by eliminating the effects of non-recurring and period-specific items, which can vary in size and frequency, and which are not necessarily reflective of the Company’s longer-term operations. The normalized non-GAAP tax rate applied to each period presented was 25%. The Company may adjust its non-GAAP tax rate as additional information becomes available and in conjunction with any other significant events occurring that may materially affect this rate, such as merger and acquisition activity, changes in business outlook, or other changes in expectations regarding tax regulations.

(2) Non-GAAP net income per diluted share may not calculate due to rounding of non-GAAP net income and diluted weighted-average shares.

Certain terms

Term	Definition
HSA	A financial account through which consumers spend and save long-term for healthcare on a tax-advantaged basis.
CDB	Consumer-directed benefits offered by employers, including flexible spending and health reimbursement arrangements ("FSAs" and "HRAs"), Consolidated Omnibus Budget Reconciliation Act ("COBRA") administration, commuter and other benefits.
HSA member	Consumers with HSAs that we serve.
Total HSA Assets	HSA members’ custodial cash assets held by our federally insured depository partners and our insurance company partners. Total HSA Assets also includes HSA members' investments in mutual funds through our custodial investment fund partner.
Client	Our employer clients.
Total Accounts	The sum of HSAs and CDBs on our platforms.
Client-held funds	Deposits held on behalf of our Clients to facilitate administration of our CDBs.
Network Partner	Our health plan partners, benefits administrators, and retirement plan recordkeepers.
Adjusted EBITDA	Adjusted earnings before interest, taxes, depreciation and amortization, amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, amortization of incremental costs to obtain a contract, costs associated with unused office space, and certain other non-operating items.
Non-GAAP net income	Calculated by adding back to GAAP net income (loss) before income taxes the following items: amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, costs associated with unused office space, and losses on extinguishment of debt, and subtracting a non-GAAP tax provision using a normalized non-GAAP tax rate.
Non-GAAP net income per diluted share	Calculated by dividing non-GAAP net income by diluted weighted-average shares outstanding.